Sclerosing solutions - Open Access .click

Results 181 to 190 of about 6,753 (222)

Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction, contributing to heightened risk of progressive liver and cardiovascular disease.
Alex E. Henney +4 more
wiley +1 more source

Elevated Polyreactive Immunoglobulin G in Immune‐Mediated Liver Injuries With the Need for Immunosuppressive Therapy

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background & Aims The distinction of drug‐induced liver injury (DILI), drug‐induced autoimmune‐like hepatitis (DI‐ALH), and autoimmune hepatitis (AIH) can be challenging due to overlapping clinical characteristics. Recently, polyreactive immunoglobulin G (pIgG) was identified as a novel biomarker in AIH.
Theresa Kirchner +18 more
wiley +1 more source

The Role of Interventional Radiology for the Treatment of Liver CE and AE Lesions: Current Concepts. [PDF]

Visc Med
Akhan O, Ciftci T.
europepmc +1 more source

Dysbiosis in the Gut‐Liver Axis Is Associated With Low Bone Mass During Murine Cholestasis

The FASEB Journal, Volume 40, Issue 6, 31 March 2026.
Dysbiosis in the gut‐liver axis drives a dysregulation in bile acid metabolism that increases bile acid efflux into systemic circulation and the bone marrow. Bile acid signaling in the marrow promotes osteoclastogenesis and suppresses osteoblastogenesis, which drives bone loss during cholestatic liver disease in mice. ABSTRACT The gut‐liver axis is the
Brooke Hutchison +7 more
wiley +1 more source

A fifteen-year retrospective analysis of varicocele embolization: evaluating success, recurrence rates and embolic agents. [PDF]